ADAG Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

3.790

Open

3.780

VWAP

3.75

Vol

59.52K

Mkt Cap

249.75M

Low

3.720

Amount

223.40K

EV/EBITDA(TTM)

--

Total Shares

66.07M

EV

197.82M

EV/OCF(TTM)

--

P/S(TTM)

23.26

Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

Show More

Events Timeline

(ET)

2026-04-17

16:20:00

Adagene Presents New Data on Muzastotug at AACR Meeting

2026-04-02 (ET)

2026-04-02

08:00:00

Adagene Reports muzastotug Study Results, 20mg/kg Cohort Confirms ORR of 31%

2026-04-02

07:40:00

Adagene Collaborates with Incyte to Evaluate New Therapy

2026-04-01 (ET)

2026-04-01

17:10:00

Adagene Reports FY25 Revenue of $7.7M

2026-01-23 (ET)

2026-01-23

08:10:00

2026 Objectives: Update on muzastotug and pembrolizumab Study

2025-12-16 (ET)

2025-12-16

07:10:00

Adagene Receives FDA Fast Track Designation for Muzastotug

News

Newsfilter

04-17Newsfilter

Muzastotug Combination Therapy Shows Significant Efficacy in Liver Cancer Treatment

Newsfilter

04-14Newsfilter

Adagene Appoints New Advisory Board Member

seekingalpha

04-02seekingalpha

Adagene Prices $70M Public Offering of ADSs

stocktwits

04-02stocktwits

Adagene Announces $70 Million Public Offering Pricing

seekingalpha

04-02seekingalpha

Adagene Prices Public Offering, Stock Drops 14%

Newsfilter

04-02Newsfilter

Adagene Prices Public Offering to Raise $70 Million

2 Analyst Rating

Wall Street analysts forecast ADAG stock price to rise

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

8.00

Averages

8.50

High

9.00

Current: 0.000

Low

8.00

Averages

8.50

High

9.00

Guggenheim

Buy

maintain

$9 -> $10

AI Analysis

2026-04-06

Reason

Guggenheim

Price Target

$9 -> $10

AI Analysis

2026-04-06

maintain

Buy

Reason

Guggenheim raised the firm's price target on Adagene to $10 from $9 and keeps a Buy rating on the shares. The firm is updating its model for FY25 earnings, the ATM offering, and modest adjustments to its assumptions for lead asset muzastotug.

Guggenheim

initiated

$9

2025-11-24

Reason

Guggenheim

Price Target

$9

2025-11-24

initiated

Reason

As previously reported, Guggenheim initiated coverage of Adagene with a Buy rating and $9 price target. The company's lead product candidate muzastotug is currently in Phase 2 for patients with late-line microsatellite stable colorectal cancer without liver metastases, notes the analyst. The company has reported "compelling" Phase 1 data for muzastotug plus pembrolizumab that exceed current standard of care benchmarks in third-line and later CRC, according to the analyst, who calls this "an area of significant unmet need."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ADAG

Unlock Now

Valuation Metrics

The current forward P/E ratio for Adagene Inc (ADAG.O) is 0.00, compared to its 5-year average forward P/E of -2.85. For a more detailed relative valuation and DCF analysis to assess Adagene Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-2.85

Current PE

0.00

Overvalued PE

-0.65

Undervalued PE

-5.05

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

13.41

Current EV/EBITDA

1251.19

Overvalued EV/EBITDA

153.27

Undervalued EV/EBITDA

-126.44

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

13.74

Current PS

138.10

Overvalued PS

32.08

Undervalued PS

-4.60

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

biopharmacudical penny stocks

Intellectia · 19 candidates

Market Cap: 50.00M - 2.00BSector: Healthcare, Healthcare Services & EquipmentIndustry: Biotechnology & Medical ResearchPrice: $0.10 - $5.00List Exchange: XNYS, XNAS, XASEIs Optionable: FalseMonthly Average Dollar Volume: >= 300,000

Ticker

Name

Market Cap$

KALA BIO Inc

177.63M

Palisade Bio Inc

390.56M

Fractyl Health Inc

81.61M

TuHURA Biosciences Inc

188.19M

Cognition Therapeutics Inc

99.18M

TScan Therapeutics Inc

61.45M

Daily momentum stocks

Intellectia · 81 candidates

Price Change Pct: >= $3.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20

Ticker

Name

Market Cap$

bioAffinity Technologies Inc

9.54M

Firefly Neuroscience Inc

39.09M

Silvaco Group Inc

154.11M

iSpecimen Inc

2.78M

Oruka Therapeutics Inc

1.94B

Sow Good Inc

6.16M

one day increase of at least 2 percent

Intellectia · 453 candidates

Region: USPrice Change Pct: >= $2.00

Ticker

Name

Market Cap$

Actelis Networks Inc

3.29M

Acurx Pharmaceuticals Inc

7.39M

Golden Sun Technology Group Ltd

5.08M

Commercial Vehicle Group Inc

59.50M

KALA BIO Inc

267.84M

Sos Ltd

12.07M

Give me some Penny Stocks that are Bullish

Intellectia · 93 candidates

Price: $0.20 - $5.00Rsi Category: moderate, overboughtMoving Average Relationship: PriceAboveMA20Month Price Change Pct: >= $10.00Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

Global Interactive Technologies Inc

10.10M

Namib Minerals

172.30M

Linkers Industries Ltd

13.97M

Liminatus Pharma Inc

49.80M

Tigo Energy Inc

282.82M

Battalion Oil Corp

46.24M

us stocks under 5$ marked to buy now

Intellectia · 85 candidates

Price: $0.50 - $5.00Analyst Consensus: Strong Buy, Moderate BuyList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

Perspective Therapeutics Inc

281.74M

cbdMD Inc

10.92M

Context Therapeutics Inc

239.80M

Acumen Pharmaceuticals Inc

157.49M

Allogene Therapeutics Inc

413.50M

Montauk Renewables Inc

247.53M

fast moving oppertunities for scalping

Intellectia · 970 candidates

Price: $1.00 - $50.00Rsi Category: moderate, overboughtRelative Vol: >= 1List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 200,000

Ticker

Name

Market Cap$

Movano Inc

15.22M

Brand Engagement Network Inc

88.16M

Direct Digital Holdings Inc

4.03M

AiRWA Inc

29.23M

Coherus Oncology Inc

248.99M

Adagene Inc

117.36M

Whales Holding ADAG

HongShan Capital Advisors Limited

Trading Trends

People Also Watch

Frequently Asked Questions

What is Adagene Inc (ADAG) stock price today?

The current price of ADAG is 3.75 USD — it has decreased -0.79

What is Adagene Inc (ADAG)'s business?

Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

What is the price predicton of ADAG Stock?

Wall Street analysts forecast ADAG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADAG is8.50 USD with a low forecast of 8.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Adagene Inc (ADAG)'s revenue for the last quarter?

Adagene Inc revenue for the last quarter amounts to NaN USD, decreased

What is Adagene Inc (ADAG)'s earnings per share (EPS) for the last quarter?

Adagene Inc. EPS for the last quarter amounts to USD, decreased

How many employees does Adagene Inc (ADAG). have?

Adagene Inc (ADAG) has 128 emplpoyees as of April 23 2026.

What is Adagene Inc (ADAG) market cap?

Today ADAG has the market capitalization of 249.75M USD.